RECURSION PHARMACEUTICALS, INC. Depreciation
RECURSION PHARMACEUTICALS, INC. (RXRX) reported Depreciation of $33.70 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-02-25
- RECURSION PHARMACEUTICALS, INC. depreciation for the quarter ending 2024-12-31 was $6.20M, a 47.62% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. depreciation for the quarter ending 2024-09-30 was $4.00M, a 4.76% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. depreciation for the quarter ending 2024-06-30 was $4.10M, a 2.50% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. depreciation for the quarter ending 2024-03-31 was $4.00M, a 11.11% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. depreciation for fiscal 2025 was $33.70M, a 84.15% increase from fiscal 2024.
- RECURSION PHARMACEUTICALS, INC. depreciation for fiscal 2024 was $18.30M, a 15.09% increase from fiscal 2023.
- RECURSION PHARMACEUTICALS, INC. depreciation for fiscal 2023 was $15.90M, a 39.47% increase from fiscal 2022.
- RECURSION PHARMACEUTICALS, INC. depreciation for fiscal 2022 was $11.40M, a 29.55% increase from fiscal 2021.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month |
|---|---|---|---|---|
| 2025-12-31 | $33.70M 10-K · filed 2026-02-25 | |||
| 2024-12-31 | $6.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $10.20M derived: sum of 2 quarters · filed 2026-02-25 | $14.30M derived: sum of 3 quarters · filed 2026-02-25 | $18.30M 10-K · filed 2026-02-25 |
| 2024-09-30 | $4.00M 10-Q · filed 2024-11-06 | $8.10M derived: sum of 2 quarters · filed 2024-11-06 | $12.10M 10-Q · filed 2024-11-06 | $16.30M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $4.10M 10-Q · filed 2024-08-08 | $8.10M 10-Q · filed 2024-08-08 | $12.30M derived: sum of 3 quarters · filed 2026-02-25 | $16.50M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $4.00M 10-Q · filed 2024-05-09 | $8.20M derived: sum of 2 quarters · filed 2026-02-25 | $12.40M derived: sum of 3 quarters · filed 2026-02-25 | $16.40M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $4.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $8.40M derived: sum of 2 quarters · filed 2026-02-25 | $12.40M derived: sum of 3 quarters · filed 2026-02-25 | $15.90M 10-K · filed 2026-02-25 |
| 2023-09-30 | $4.20M 10-Q · filed 2024-11-06 | $8.20M derived: sum of 2 quarters · filed 2024-11-06 | $11.70M 10-Q · filed 2024-11-06 | $14.90M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $4.00M 10-Q · filed 2024-08-08 | $7.50M 10-Q · filed 2024-08-08 | $10.70M derived: sum of 3 quarters · filed 2025-02-28 | $13.60M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $3.60M 10-Q · filed 2024-05-09 | $6.70M derived: sum of 2 quarters · filed 2025-02-28 | $9.60M derived: sum of 3 quarters · filed 2025-02-28 | $12.30M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $3.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $6.00M derived: sum of 2 quarters · filed 2025-02-28 | $8.70M derived: sum of 3 quarters · filed 2025-02-28 | $11.40M 10-K · filed 2025-02-28 |
| 2022-09-30 | $2.90M 10-Q · filed 2023-11-09 | $5.60M derived: sum of 2 quarters · filed 2023-11-09 | $8.30M 10-Q · filed 2023-11-09 | $10.80M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $2.70M 10-Q · filed 2023-08-08 | $5.40M 10-Q · filed 2023-08-08 | $7.90M derived: sum of 3 quarters · filed 2024-02-29 | $10.40M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $2.70M 10-Q · filed 2023-05-08 | $5.20M derived: sum of 2 quarters · filed 2024-02-29 | $7.70M derived: sum of 3 quarters · filed 2024-02-29 | $10.10M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $2.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $5.00M derived: sum of 2 quarters · filed 2024-02-29 | $7.40M derived: sum of 3 quarters · filed 2024-02-29 | $8.80M 10-K · filed 2024-02-29 |
| 2021-09-30 | $2.50M 10-Q · filed 2022-11-08 | $4.90M derived: sum of 2 quarters · filed 2022-11-08 | $6.30M 10-Q · filed 2022-11-08 | $7.40M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $2.40M 10-Q · filed 2022-08-09 | $3.80M 10-Q · filed 2022-08-09 | $4.90M derived: sum of 3 quarters · filed 2023-02-27 | $6.00M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $1.40M 10-Q · filed 2022-05-10 | $2.50M derived: sum of 2 quarters · filed 2023-02-27 | $3.60M derived: sum of 3 quarters · filed 2023-02-27 | $4.60M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $2.20M derived: sum of 2 quarters · filed 2023-02-27 | $3.20M derived: sum of 3 quarters · filed 2023-02-27 | $4.20M 10-K · filed 2023-02-27 |
| 2020-09-30 | $1.10M 10-Q · filed 2021-11-10 | $2.10M derived: sum of 2 quarters · filed 2021-11-10 | $3.10M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $1.00M 10-Q · filed 2021-08-13 | $2.00M 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | $1.00M 10-Q · filed 2021-05-12 | |||
| 2019-12-31 | $3.50M 10-K · filed 2022-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |